Jul 2026· Journal of Drug Delivery and Therapeutics· Vol 16, pp. 195-207· 0 citations· 133 references
TL;DR
This review examines the current applications of machine learning, deep learning, reinforcement learning, and generative AI architectures across the pharmaceutical product lifecycle, from target identification and lead optimization to dosage form development and clinical translation.
Abstract
Artificial intelligence (AI) is rapidly reshaping pharmaceutics and drug delivery, offering computational alternatives to traditional trial-and-error approaches in formulation design, nanocarrier engineering, and manufacturing. This review examines the current applications of machine learning, deep learning, reinforcement learning, and generative AI architectures across the pharmaceutical product lifecycle, from target identification and lead optimization to dosage form development and clinical translation. Particular attention is given to AI-driven prediction of excipient compatibility, formulation stability, and bioavailability, as well as the design of smart nanocarriers, stimuli-responsive delivery systems, and 3D-printed dosage forms enabled by graph neural networks, transformer-based models, and Bayesian optimization techniques. The review also traces the historical evolution of computational pharmaceutics, from early rule-based prediction systems to current high-throughput, automation-integrated platforms, and highlights emerging tools such as digital twins, federated learning frameworks, and AI-supported nanorobotics for targeted intracellular delivery. Despite these advances, significant challenges persist, including limited data availability and standardization, algorithmic opacity and the demand for explainable AI, and the absence of harmonized regulatory frameworks for validating AI-driven decision-making in drug development. The review further considers data quality and interpretability concerns specific to nanomedicine, alongside the regulatory and ethical considerations necessary for clinical adoption. Future directions emphasize the integration of multi-omics data, real-time adaptive drug delivery systems, and quantum-AI convergence to advance personalized medicine. Addressing these barriers through interdisciplinary collaboration, standardized data repositories, and transparent regulatory guidance will be essential to translating AI-enabled pharmaceutical innovations from computational design into safe, effective clinical therapeutics.
Keywords: Artificial intelligence; machine learning; drug delivery; nanomedicine; formulation design; personalized medicine; deep learning; pharmaceutics
INTRODUCTION
Liposomal drug delivery systems have achieved notable clinical success; however, their wider translation is often limited by complex formulation variables, unpredictable process behavior, and scalability challenges. Traditional trial-and-error optimization strategies struggle to address the nonlinear relat...
Pravin Kumar, Sunny Bhardwaj, Ajay Kumar et al.· Recent Advances in Drug Deli...· 0 citations
Problem: Coumarin derivatives exhibit broad pharmacological activities and substantial therapeutic potential, yet the integration of artificial intelligence (AI)with chemical engineering across their discovery, synthesis, optimization, and pharmaceutical manufacturing remains fragmented. Aim: This review critically eva...
Y. Mustafa· Artificial Intelligence and...· 0 citations
OBJECTIVE
This review presents Darwinian nanomedicine as an artificial intelligence (AI)-enabled drug delivery strategy that applies Darwinian evolutionary principles as a computational and engineering analogy. Rather than implying biological evolution of nanoparticles, the framework employs iterative cycles of variati...
C. Belkare, O. Daware· Drug Development and Industr...· 0 citations
This review provides a structured overview of AI applications in nanotechnology, including data-driven nanomaterial discovery and inverse design using machine learning (ML) and generative models, optimization of nanoparticle synthesis through Bayesian optimization and self-driving laboratories, targeted drug delivery a...
Background Artificial intelligence (AI) has rapidly emerged as a powerful tool for accelerating the design and optimization of nanoparticle‐based drug delivery systems (NDDSs). By analyzing complex multidimensional datasets, AI models can predict nanoparticle physicochemical properties, biodistribution, and safety prof...
Razan Haddad· Advances in pharmacological...· 0 citations
This paper examines and views the new innovations in combining the use of AI into harmonized medication design and targeted delivery systems, and analyzes AI-driven molecular design with synthetic level reports, emphasizing explainable AI, digital twin platforms, and translations that characterize the next generation o...